Tandem Diabetes Care, Inc. (TNDM) Reaches $2.36 After 7.00% Down Move; Last Week CBIZ, Inc. (CBZ) Coverage

February 15, 2018 - By Clifton Ray

The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a huge mover today! The stock decreased 5.60% or $0.14 during the last trading session, reaching $2.36. About 440,993 shares traded. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has declined 86.78% since February 15, 2017 and is downtrending. It has underperformed by 103.48% the S&P500.The move comes after 9 months negative chart setup for the $23.88 million company. It was reported on Feb, 15 by Barchart.com. We have $2.19 PT which if reached, will make NASDAQ:TNDM worth $1.67M less.

Among 2 analysts covering CBIZ (NYSE:CBZ), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CBIZ had 6 analyst reports since October 7, 2015 according to SRatingsIntel. The company was initiated on Tuesday, July 19 by Sidoti. The rating was downgraded by Sidoti on Tuesday, October 13 to “Neutral”. The stock of CBIZ, Inc. (NYSE:CBZ) has “Equal-Weight” rating given on Tuesday, March 15 by First Analysis. The rating was downgraded by First Analysis to “Equal-Weight” on Wednesday, October 7. The stock of CBIZ, Inc. (NYSE:CBZ) has “Buy” rating given on Thursday, January 21 by Sidoti. First Analysis downgraded it to “Underweight” rating and $9.50 target in Thursday, October 29 report. See CBIZ, Inc. (NYSE:CBZ) latest ratings:




The stock increased 11.38% or $1.85 during the last trading session, reaching $18.1. About 80,484 shares traded. CBIZ, Inc. (NYSE:CBZ) has risen 47.49% since February 15, 2017 and is uptrending. It has outperformed by 30.79% the S&P500.

Since August 31, 2017, it had 0 insider buys, and 6 insider sales for $2.20 million activity. 33,731 CBIZ, Inc. (NYSE:CBZ) shares with value of $506,507 were sold by GERARD STEVEN L. On Tuesday, December 12 the insider Kouzelos Michael P sold $523,250. The insider GROVE WARE H sold $376,515. Shares for $246,724 were sold by SPURIO CHRIS.

CBIZ, Inc., through its subsidiaries, provides professional business services, products, and solutions in the United States and Canada. The company has market cap of $979.30 million. It offers its services through three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. It has a 22.26 P/E ratio. The Financial Services practice group provides accounting and tax, government health care consulting, financial advisory, valuation, litigation support, risk and advisory, real estate consulting, and internal audit outsourcing services.

Investors sentiment is 1.82 in 2017 Q3. Its the same as in 2017Q2. It is without change, as 8 investors sold CBIZ, Inc. shares while 31 reduced holdings. only 17 funds opened positions while 54 raised stakes. 46.06 million shares or 0.80% less from 46.43 million shares in 2017Q2 were reported. Geode Management Limited Liability Corporation holds 0% or 468,159 shares. 51,083 were accumulated by Royal Bank Of Canada. Pnc Fincl Service Group Incorporated, a Pennsylvania-based fund reported 338 shares. Aperio Gp Ltd Liability has 41,482 shares for 0% of their portfolio. Moreover, Amer Int Group has 0% invested in CBIZ, Inc. (NYSE:CBZ). P2 Prtn, a New York-based fund reported 2.36M shares. Zacks Invest invested in 181,012 shares or 0.07% of the stock. First Manhattan invested in 0.23% or 2.49 million shares. The Maryland-based Campbell Investment Adviser Llc has invested 0.35% in CBIZ, Inc. (NYSE:CBZ). Federated Invsts Pa holds 386 shares. Private Advisor Group Inc reported 138,375 shares or 0.06% of all its holdings. Brandywine Glob Inv Management Ltd Liability Company, a Pennsylvania-based fund reported 35,726 shares. Ameritas Partners holds 0% of its portfolio in CBIZ, Inc. (NYSE:CBZ) for 4,490 shares. Blackrock Incorporated invested in 0% or 3.32M shares. Parametric Port Lc owns 147,238 shares or 0% of their US portfolio.

Among 9 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Tandem Diabetes Care had 20 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush maintained Tandem Diabetes Care, Inc. (NASDAQ:TNDM) on Wednesday, November 2 with “Outperform” rating. Stifel Nicolaus downgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rating on Wednesday, November 2. Stifel Nicolaus has “Hold” rating and $3.50 target. Robert W. Baird downgraded the stock to “Neutral” rating in Wednesday, November 2 report. On Thursday, March 24 the stock rating was downgraded by Bank of America to “Underperform”. The rating was downgraded by PiperJaffray to “Neutral” on Thursday, November 3. Zacks downgraded the shares of TNDM in report on Thursday, August 20 to “Buy” rating. The rating was maintained by Piper Jaffray on Thursday, October 5 with “Hold”. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Buy” rating given on Monday, August 10 by Deutsche Bank. The stock has “Neutral” rating by Piper Jaffray on Thursday, November 3. Zacks downgraded the stock to “Buy” rating in Friday, August 28 report.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $23.88 million. The companyÂ’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

Analysts await Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to report earnings on March, 14. They expect $-1.30 earnings per share, up 72.92% or $3.50 from last year’s $-4.8 per share. After $-3.09 actual earnings per share reported by Tandem Diabetes Care, Inc. for the previous quarter, Wall Street now forecasts -57.93% EPS growth.

Investors sentiment increased to 0.59 in 2017 Q3. Its up 0.04, from 0.55 in 2017Q2. It is positive, as 24 investors sold Tandem Diabetes Care, Inc. shares while 8 reduced holdings. 10 funds opened positions while 9 raised stakes. 7.03 million shares or 59.85% less from 17.51 million shares in 2017Q2 were reported. Appleton Prtn Ma owns 26,700 shares for 0% of their portfolio. Meeder Asset Mngmt Incorporated reported 2,589 shares stake. Ameriprise holds 0% or 10,000 shares. Blackrock owns 419,400 shares or 0% of their US portfolio. Royal Comml Bank Of Canada holds 0% of its portfolio in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for 2,816 shares. Davenport & Limited Liability accumulated 125,000 shares or 0% of the stock. Bnp Paribas Arbitrage reported 0% in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). Citigroup owns 10,000 shares. 2.50 million are held by Tpg (Sbs) Advisors Incorporated. Northern has 50,678 shares. Jacobs Levy Equity Mngmt Inc, a New Jersey-based fund reported 238,852 shares. Deutsche Bancorp Ag has invested 0% in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). Adage Cap Partners Gp Limited Liability Corp holds 0% or 500,000 shares in its portfolio. Bank & Trust Of New York Mellon Corporation, New York-based fund reported 12,850 shares. Pnc Svcs owns 115 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.